Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT00630786
First received: February 28, 2008
Last updated: February 5, 2014
Last verified: February 2014
  Purpose

This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.


Condition Intervention Phase
Colon Cancer
Colorectal Cancer
Rectal Cancer
Metastatic Colorectal Cancer
Oncology
Drug: Panitumumab
Drug: Conatumumab
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Trial of AMG 655 in Combination With Panitumumab in Subjects With Metastatic Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • Part 1: Number of Participants With Dose-limiting Toxicities [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

    A dose-limiting toxicity (DLT) was defined as any grade 3 or 4 conatumumab-related or combination (panitumumab and conatumumab)-related adverse event, or grade 3 or 4 laboratory abnormality that occurred during the first 4 weeks (28 days) of treatment with panitumumab and conatumumab. Anemia and lymphopenia were not considered DLTs.

    Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 was used to grade all adverse events and toxicities.


  • Number of Participants With an Objective Response [ Time Frame: Participants were evaluated for tumor response until radiographic disease progression or until the participant began another anticancer treatment (up to a maximum of 55.6 weeks). ] [ Designated as safety issue: No ]
    An overall objective response of either a confirmed complete response or partial response, where the overall objective response was equivalent to the best overall response recorded for each participant from enrollment until disease progression or recurrence. Tumor response was assessed by the investigator according to the modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Responses were confirmed no less than 4 weeks after the criteria for response were first met. Complete response defined as the disappearance of all target and non-target lesions and no new lesions. Partial response defined as either the disappearance of all target lesions with the persistence of one or more non-target lesion(s), or, at least a 30% decrease in the sum of the longest diameter (SLD) of target lesions, taking as reference the Baseline SLD and the disappearance of all or the persistence of 1 or more non-target lesions.


Secondary Outcome Measures:
  • Progression-free Survival [ Time Frame: Participants were evaluated for tumor response until radiographic disease progression or until the participant began another anticancer treatment (up to a maximum of 55.6 weeks). ] [ Designated as safety issue: No ]
    Kaplan-Meier estimate of the median time from enrollment to death from any cause or disease progression. Progressive disease is defined as at least a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the nadir SLD recorded since the treatment started, or the appearance of one or more new lesions, or the unequivocal progression of existing non-target lesions.

  • Overall Survival [ Time Frame: Participants were evaluated for tumor response until radiographic disease progression or until the participant began another anticancer treatment (up to a maximum of 55.6 weeks). ] [ Designated as safety issue: No ]
    Kaplan-Meier estimate of time from enrollment to death from any cause

  • Number of Participants With Disease Control [ Time Frame: Participants were evaluated for tumor response until radiographic disease progression or until the participant began another anticancer treatment (up to a maximum of 55.6 weeks). ] [ Designated as safety issue: No ]
    Disease control defined as participants with an overall objective response of complete response (CR), partial response (PR), or stable disease during the treatment period, assessed by the investigator according to the modified Response Evaluation Criteria in Solid Tumors (RECIST). Responses were confirmed no less than 4 weeks after the criteria for response were first met. CR defined as the disappearance of all target and non-target lesions and no new lesions. PR defined as either the disappearance of all target lesions with the persistence of one or more non-target lesion(s), or, at least a 30% decrease in the sum of the longest diameter (SLD) of target lesions, taking as reference the Baseline SLD and the disappearance of all or the persistence of 1 or more non-target lesions. Stable disease defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the nadir LD since the treatment started.

  • Time to Response [ Time Frame: Participants were evaluated for tumor response until radiographic disease progression or until the participant began another anticancer treatment (up to a maximum of 55.6 weeks). ] [ Designated as safety issue: No ]
    The interval in days from the first dose of study therapy to the date of first confirmed objective response. Calculated only for participants with an objective response.

  • Duation of Response [ Time Frame: Participants were evaluated for tumor response until radiographic disease progression or until the participant began another anticancer treatment (up to a maximum of 55.6 weeks). ] [ Designated as safety issue: No ]
    The interval in days from the first confirmed objective response to disease progression per the modified RECIST criteria or death. Calculated only for participants with an objective response.

  • Number of Participants With Anti-therapeutic Antibodies [ Time Frame: Antibody samples were collected at weeks 1, 7, and 23 and every 6 months thereafter during treatment, and at the safety follow-up and follow-up visits. The mean follow-up time was 35.7 weeks. ] [ Designated as safety issue: No ]
    Number of participants with human anti-panitumumab antibodies (HAPA) or anti-conatumumab antibodies measured by immunoassay.

  • Number of Participants With Adverse Events (AEs) [ Time Frame: From first dose of investigational drug until 30 days after the last dose, up to a maximum of 50 weeks. ] [ Designated as safety issue: No ]

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment, and includes any such occurrence (eg, sign, symptom, or diagnosis) or worsening of a pre-existing medical condition from the time that a participant has signed informed consent to the time of initiation of investigational product. The severity of AEs was graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, according to the following:

    1. = Mild: Aware of sign or symptom, but easily tolerated
    2. = Moderate: Discomfort enough to cause interference with usual activity;
    3. = Severe: Incapacitating with inability to work or do usual activity;
    4. = Life-threatening: an event in which the patient was, in the view of the investigator, at risk of death at the time of the event;
    5. = Fatal.

  • Number of Participants With Post-baseline Laboratory Values Grade 3 or Higher [ Time Frame: From first dose of investigational drug until 30 days after the last dose, up to a maximum of 50 weeks. ] [ Designated as safety issue: No ]
    Laboratory values were assessed using the National Cancer Institute (NCI) Common Toxicity Criteria (version 3.0) according to the following: 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Life-threatening; 5 = Fatal.


Enrollment: 53
Study Start Date: January 2008
Study Completion Date: November 2010
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Panitumumab plus conatumumab
Participants received 10 mg/kg conatumumab and 6 mg/kg panitumumab administered on the same day by sequential intravenous (IV) infusions once every 2 weeks until progressive disease, intolerability, withdrawal, or death.
Drug: Panitumumab
Administered by intravenous infusion
Other Name: Vectibix®
Drug: Conatumumab
Administered by intravenous infusion
Other Name: AMG 655

Detailed Description:

This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.

The objective for Part 1 is to identify a tolerable dose of conatumumab in combination with panitumumab based on the incidence of dose-limiting toxicities in patients with Metastatic Colorectal Cancer.

The objective for Part 2 is to evaluate the objective response rate stratified by Kirsten Rat Sarcoma Virus Oncogene (KRAS) status (wild-type versus mutant) in patients with Metastatic Colorectal Cancer treated with the combination of panitumumab and conatumumab (tolerable dose identified in part 1).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum
  • Radiographically documented disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) during or following treatment with fluoropyrimidine, irinotecan, and/or oxaliplatin chemotherapy for Metastatic Colorectal Cancer. Progressive disease must be documented during or ≤ 6 months after the last dose of the most recent chemotherapy regimen prior to enrollment.
  • At least 1 uni-dimensionally measurable lesion measuring ≥ 20 mm in one dimension per modified RECIST. Lesion must not be chosen from a previously irradiated field, unless there has been documented disease progression in that field after irradiation and prior to enrollment. All sites of disease must be evaluated.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Available archived paraffin-embedded tumor tissue from the primary tumor or metastasis for submission to the central laboratory
  • Man or woman ≥ 18 years of age at the time of enrollment
  • Hematologic function within the following limits:

    • Absolute neutrophil count (ANC) > 1.0 x 10^9 cells/L
    • Platelets ≥ 100 x 10^9/L
  • Renal function within the following limits:

    • Creatinine < 2.0 mg/dL
  • Hepatic function within the following limits:

    • Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN) (≤ 5 x ULN if liver metastases)
    • Alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases)
    • Bilirubin ≤ 2 x ULN
  • Metabolic function within the following limits:

    • Amylase ≤ 2 x ULN
    • Lipase ≤ 2 x ULN
    • Magnesium ≥ lower limit of normal
  • Negative pregnancy test ≤ 72 hours before enrollment (for woman of childbearing potential only)
  • Must have received 1, 2, or 3 prior chemotherapy regimens for Metastatic Colorectal Cancer
  • Competent to comprehend, sign, and date the independent ethics committee/institutional review board (IEC/IRB) approved written informed consent

Exclusion Criteria:

  • History of other primary cancer, unless:

    • Curatively resected non-melanomatous skin cancer
    • Curatively treated cervical carcinoma in situ
    • Other primary solid tumor curatively treated with no known active disease present and no treatment administered for ≥ 5 years before enrollment
  • Prior treatment with anti-epidermal growth factor receptor (EGFr) inhibitors (eg, cetuximab, erlotinib, gefitinib), unless treatment was received in the adjuvant setting ≥ 6 months before enrollment
  • Use of systemic chemotherapy and radiotherapy ≤ 30 days before enrollment
  • Use of prior anti-tumor therapies with a short serum half-life (less than 1 week) including prior experimental agents or approved anti-tumor small molecules ≤ 30 days before enrollment
  • Use of anti-tumor therapies with a longer serum half-life (eg, bevacizumab) including prior experimental or approved protein/antibodies ≤ 42 days before enrollment
  • Any investigational agent or therapy ≤ 30 days before enrollment
  • Known allergy or hypersensitivity to any component of panitumumab and/or AMG 655
  • History of or known presence of central nervous system (CNS) metastases
  • History of interstitial lung disease (eg, pneumonitis, pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computerized tomography (CT) scan
  • Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment
  • Active inflammatory bowel disease or other active bowel disease causing chronic diarrhea (defined as ≥ Common Terminology Criteria for Adverse Events [CTCAE] grade 2 [CTCAE version 3.0])
  • Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic hepatitis B infection
  • Any co-morbid disease or condition that could increase the risk of toxicity (eg, significant ascites, significant pleural effusion)
  • Any uncontrolled concurrent illness (eg, infection, bleeding) or history of any medical condition that may interfere with the interpretation of the study results
  • Major surgical procedure (requiring general anesthesia) ≤ 28 days or minor surgical procedure (excluding central venous catheter placement) ≤ 14 days before enrollment. Patients must have recovered from surgery related toxicities.
  • Other investigational procedures are excluded
  • Patient is currently pregnant or breast feeding
  • Man or woman of childbearing potential who is not willing to use adequate contraceptive precautions during treatment and for 6 months (for women) or 1 month (for men) after the last investigational product administration. Adequate contraceptive precautions includes double barrier contraceptive methods (eg, diaphragm and condom) or abstinence.
  • Previously enrolled into this study
  • Patient unwilling or unable to comply with study requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00630786

Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided

Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT00630786     History of Changes
Other Study ID Numbers: 20060332, 2007-004722-25
Study First Received: February 28, 2008
Results First Received: August 6, 2010
Last Updated: February 5, 2014
Health Authority: Belgium: Federal Public Service (FPS) Health, Food Chain Safety and Environment
EU: CHMP
France: Ministry of Health
Germany: Federal Institute for Drugs and Medical Devices
United States: Food and Drug Administration
United States: Institutional Review Board
United States: Western Institutional Review Board

Additional relevant MeSH terms:
Colonic Neoplasms
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 24, 2014